SPOTLIGHT -
The Value of Guidelines: Discussing the New International Guidelines for Algorithmic Treatment of Schizophrenia
Clinician's can use the new international guidelines for schizophrenia treatment to solidify treatment decisions and improve patient outcomes.
A Conversation About the Clozapine REMS
An FDA committee recently decided the clozapine REMS protocol was no longer necessary. How will this impact clinicians?
The New Approach to Schizophrenia: An Honest Conversation About Cobenfy
The authors of the Clinician's Corner column discuss the latest FDA-approved treatment for schizophrenia.
To Be or Not to Be? Understanding False Positives in Bipolar Diagnosis
The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis.
Depression With Anhedonia vs Dysthymia: Do We Understand the Difference?
Diagnostic clarity between anhedonia and persistent depressive disorder is paramount in clinical practice to ensure effective and safe treatment for patients.
